BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 4, 2011
View Archived Issues
Several inhibitors of botulinum neurotoxins presented at Pacifichem 2010
Read More
Replacement of alpha-L-iduronidase at birth shows promise to treat mucopolysaccharidosis
Read More
Sorafenib monotherapy ineffective in patients with advanced melanoma
Read More
KPT-127 is toxic to hematological cancer cells
Read More
Astellas Pharma reflects on Q2 of fiscal year 2010
Read More
AstraZeneca researchers patent novel DPPI inhibitors
Read More
New antagonists of melanin-concentrating hormone MCH1 receptor identified
Read More
New ligands of trace amine-associated receptor 1 described
Read More
Repros Therapeutics receives approval for phase IIb Androxal trial
Read More
OSI scientists discover novel anticancer FADK 1 inhibitors
Read More
Inspire Pharma reports on second phase III denufosol trial in cystic fibrosis
Read More
Labopharm and Purdue Pharma amend license agreement for Ryzolt
Read More
ReCyte Therapeutics to develop treatments for cardiovascular and blood diseases
Read More
Advanced Cell Technology cleared to test MA-09-HRPE in AMD
Read More
Janssen claims new inhibitors of fatty-acid amide hydrolase 1
Read More
Veridex, Massachusetts General Hospital and Johnson & Johnson join to develop CTC technology
Read More
Senesco's SNS01-T obtains FDA orphan drug status in multiple myeloma
Read More
Juventas begins phase II trial of JVS-100 for critical limb ischemia
Read More
FDA approves Tibotec's Intelence 200-mg formulation
Read More
BTZO-1 and BTZO-2 exhibit cardioprotective activity in vitro
Read More
Celera files premarketing approval application with FDA for KIF6 Genotyping Assay
Read More
POL-6326 is well tolerated and effectively mobilizes hematopoietic stem cells in phase II trial
Read More
Stryker completes purchase of Boston Scientific's neurovascular business
Read More